Media stories about Dermira (NASDAQ:DERM) have been trending somewhat negative recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dermira earned a daily sentiment score of -0.04 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.5769073687967 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of research firms have weighed in on DERM. Mizuho downgraded Dermira from a “buy” rating to a “neutral” rating in a research note on Monday, March 5th. Guggenheim assumed coverage on Dermira in a report on Tuesday, December 5th. They set a “buy” rating for the company. BidaskClub raised Dermira from a “sell” rating to a “hold” rating in a report on Thursday. Cantor Fitzgerald set a $20.00 price target on Dermira and gave the stock a “buy” rating in a report on Monday, March 5th. Finally, Leerink Swann lifted their price target on Dermira from $42.00 to $48.00 and gave the stock an “outperform” rating in a report on Wednesday, January 17th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Dermira has an average rating of “Buy” and an average target price of $32.71.
Dermira stock traded down $0.17 during trading on Monday, reaching $8.93. The company’s stock had a trading volume of 659,389 shares, compared to its average volume of 1,669,801. Dermira has a 12-month low of $8.55 and a 12-month high of $36.21. The company has a debt-to-equity ratio of 1.87, a quick ratio of 5.28 and a current ratio of 5.28. The company has a market cap of $380.58, a price-to-earnings ratio of -1.22 and a beta of 0.86.
In other news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $27.07, for a total value of $81,210.00. Following the transaction, the insider now directly owns 5,802 shares of the company’s stock, valued at approximately $157,060.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total value of $499,288.90. The disclosure for this sale can be found here. Insiders have sold a total of 26,758 shares of company stock worth $728,459 over the last ninety days. Company insiders own 13.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/19/dermira-derm-earns-daily-coverage-optimism-rating-of-0-04/2019158.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.